Rhythm Pharmaceuticals (RYTM) was raised to a "buy" recommendation by an influential sell-side firm Monday. Shares of this commercial-stage biopharmaceutical company have soared sharply in recent weeks so we want to see how we should proceed.




Rhythm Pharmaceuticals (RYTM) was raised to a "buy" recommendation by an influential sell-side firm Monday. Shares of this commercial-stage biopharmaceutical company have soared sharply in recent weeks so we want to see how we should proceed.
Let's check out the charts and indicators for clues.
With about six months to go, anything can happen for the 2023 Tax Loss Selling Recovery Portfolio.
Even the bulls will likely agree that this market needs better participation and breadth.
This 'best-in-class' cybersecurity name was already hot, before the news.
This pair of household names easily could pull back based on the economic challenges ahead.
We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.
Email Real Money's Wall Street Pros for further analysis and insight
Already a Subscriber? Login
Follow Real Money's Wall Street Pros to receive real-time investing alerts
Already a Subscriber? Login